Search Results
Showing 25 of 52 results
Why Teva is Investing Over One Billion Dollars in Biologics in Europe
With demand for biopharmaceutical products on the rise Teva is investing in biologics production technologies for Active Pharmaceutical Ingredients APIs with cells for biosimilars and novel biologics We meet Teva teams on the ground in the biologics manufacturing and supply operations site in Ulm to find out more
Biosimilars are advancing more treatment options for patients
Cory Wohlbach is responsible for steering Teva s new biosimilar products through the regulatory approval process He explains what biosimilars are how they have the potential to reduce costs for patients and how patient safety is always a top priority
Biopharmaceuticals at Teva
Discover what biopharmaceuticals are and how Teva Pharmaceuticals does invest in this domain
Biopharmaceuticals
Teva Pharmaceuticals is investing in original biologic medicines and in biosimilars focusing central nervous system respiratory conditions and in oncology
Our goal is to lead the field of biosimilars just like we lead in generic medicines
Dr Nir Shapir VP of Teva s global research and development team and CMC Biosimilars division discusses Teva s entry into the biosimilars market and the complexity of manufacturing biopharmaceuticals Read the interview with Haaretz reprinted with permission
Biosimilar Medicine Has Made a Difference to My Life
Rachna Sood Project Manager Employee Experience with Teva UK was diagnosed with the autoimmune condition lupus more than 20 years ago She talks about the important medicines that help her to manage her condition
Contributing to Healthy Communities
Teva Pharmaceuticals is committed to making a positive impact for healthier communities
New R D Facility in Hungary will Double Annual Testing Capability
Go behind the scenes at Teva to Debrecen in Hungary where a new 2 4 million R D facility is helping to speed up production and get medicines to patients faster
Research Development
Teva s Global R D organization is devoted to the development of new medicines devices and combination products that provide meaningful therapeutic benefit
Meet Our People Stefan Ottmar
Stefan Ottmar Fuegenschuh is the Site General Manager for Teva s biologics site in Ulm Germany He describes the fascinating world of biotechnology and the work his team is doing on project Genesis which will expend Teva s biotech manufacturing capabilities
Company Info Teva in Facts and Figures
Learn about Teva Pharmaceuticals history and explore company info See how we achieve our vision to be a global leader in generics and biopharmaceuticals
Teva Innovative Medicine Biosimilar Project Pipeline
Teva s Global R D organization is devoted to the development of new medicines devices and combination products that provide meaningful therapeutic benefit
